心脉医疗(688016) - 2024-002投资者关系活动记录表

Financial Performance - In Q1 2024, the company achieved total revenue of 358 million yuan, a year-on-year increase of 25.38% [1] - Net profit attributable to the parent company was 183 million yuan, up 48.01% compared to the same period last year [2] - Basic earnings per share reached 2.23 yuan, reflecting a growth of 28.90% year-on-year [2] Product Market Coverage - The Castor branched aortic stent and delivery system has covered over 1,000 terminal hospitals [2] - The Minos abdominal aortic stent and delivery system has reached over 850 terminal hospitals [2] - The ReewarmPTX drug balloon dilation catheter has been adopted by over 950 terminal hospitals [2] - New products like the Fontus branched intraoperative stent system and Talos straight thoracic aortic stent system have entered over 200 hospitals each [2] Global Expansion - The company has obtained 43 overseas registration certificates, with clinical applications in 34 countries including Europe, Latin America, and Southeast Asia [2] - The European market contributes nearly 3% market share, making it a key target for short to mid-term expansion [3] - The company plans to further penetrate markets in Brazil, Argentina, and Chile [3] R&D and Cost Management - Increased sales of both new and existing products have driven profit growth [2] - Cost reduction measures have been effectively implemented, leading to a decrease in R&D expense ratio [2] - The company is prioritizing high-potential projects while slowing down lower-priority ones to ensure long-term competitiveness [2] Future Outlook - The impact of centralized procurement on the domestic market remains uncertain, with potential effects expected in 2025 [3] - The company is adjusting its R&D team structure to focus on high-priority projects for better economic returns [4]